Spirit Scientific, a regenerative medicine startup from New Taipei City, Taiwan, officially entered the Japanese market in 2023. The company focuses on Platelet-Rich Plasma (PRP) therapy, leveraging its innovative platelet lyophilization technology for long-term preservation as a key competitive advantage. Their goal is to popularize and advance the clinical application of this treatment.
Strategic Expansion and Growth
Spirit Scientific chose Japan as its first international market due to its well-established regulatory framework for regenerative medicine, which provides a supportive environment for clinical and commercial applications. The company also recognized Japan’s significant market size and high medical quality.
In Taiwan, PRP therapy is already widely used in approximately 1,300 clinics, spanning dermatology, plastic surgery, and orthopedics. To support its growth, Spirit Scientific opened its third cleanroom-equipped production laboratory in Tokyo’s Ariake district in late 2024. This facility will be crucial for pilot production and process validation, laying the groundwork for large-scale manufacturing and supply chain establishment.
Building on its Japanese foothold, Spirit Scientific plans to expand into European and American markets starting in 2026.
This excerpt from the Nikkei special feature, “Learning from Taiwan, the Strongest in the Digital World – The Resilience Created by TSMC and Foxconn,” highlights Spirit Scientific’s strategic international growth driven by technological innovation and market insight, positioning them for a significant role on the global regenerative medicine stage.
Source from Nikkei Asia, Learning from Taiwan, the strongest in the digital world – The ability of TSMC and Foxconn to break through adversity
